News from ESMO: NADINA Trial Update in Stage III Melanoma
A follow-up report with data from NADINA was presented at the European Society for Medical Oncology (ESMO) Congress on September…
Melanoma Research
09/14/2024
News from ESMO: NADINA Trial Update in Stage III Melanoma
A follow-up report with data from NADINA was presented at the European Society for Medical Oncology (ESMO) Congress on September…
|
08/26/2024
New Specialty Manages Skin Concerns and Keeps Patients on Therapy
Cancer treatment—including and especially melanoma—unfortunately, produces a risk of side effects impacting the feeling and vitality of the skin. Changes…
|
07/18/2024
Everything Coming up Rosy is not a Health Tune
People with the chronic inflammatory skin condition rosacea shouldn’t skip out on check-ups. According to a new research study from…
|
07/02/2024
Summary of Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
By Mandi Murph Treatment may be changing for patients with Stage III melanoma. Recent clinical trial results show improved outcomes…
|
07/02/2024
In Plain English: Overview of the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO)
By Kim Margolin, M.D., FACP, FASCO The American Society of Clinical Oncology or ASCO is a professional organization that…
|
|
06/06/2024
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in…
|
|
04/11/2024
Interview with Allison Betof Warner, MD, PhD: TIL Therapy
The following is an edited and shortened version of our recent interview with Allison Betof Warner, MD, PhD about the…
|
04/11/2024
In Plain English: Tumor-Infiltrating Lymphocyte (“TIL”) Therapy for Advanced Melanoma
By Kim Margolin, M.D., FACP, FASCO Note: We are rerunning an update on this TIL therapy article that originally ran…
|
|
03/15/2024
The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma
An exciting new development in melanoma treatment is the recent FDA approval of Lifileucel (AMTAVGI) therapy, which harnesses the power…
|
|
02/17/2024
Iovance Biotherapeutics Announces Approval for TIL Therapy
The Food and Drug Administration approval provides another option for advanced, refractory melanoma February 16, 2024 (Richmond, California) The FDA…
|
|
Recent Posts
Apr. 28, 2025
Your Style Can Save Lives – Lilly Pulitzer Giving Day is Here!
Apr. 28, 2025
From Diagnosis to Crown: Miss Pennsylvania’s Journey of Advocacy and Awareness
Apr. 24, 2025
Worried Your Melanoma Treatment Isn’t Working?
Apr. 24, 2025
Genetic Testing Performed in Melanoma
Apr. 16, 2025